Shaikh Irshad, Askari Alan, Ourû Suzana, Warusavitarne Janindra, Athanasiou Thanos, Faiz Omar
St Mark's Hospital, Imperial College London, Watford Road, Harrow, Middlesex, England, HA1 3UJ, UK,
Int J Colorectal Dis. 2015 Jan;30(1):19-29. doi: 10.1007/s00384-014-2045-1. Epub 2014 Nov 4.
Low rectal cancer is conventionally managed with neoadjuvant chemoradiotherapy (CRT) followed by radical surgery (RS). In patients who refuse a stoma or are unfit for RS, an alternative approach may be the use of pre-op CRT and local excision (LE) where tumours are responsive. The aim of this systematic review is to determine whether differences exist in local recurrence (LR), overall survival (OS) and disease-free (DFS) survival between patients treated with CRT + LE and CRT + RS.
A literature search was performed using MEDLINE/PubMed/Ovid databases and Google Scholar between 1946 and 2013. Studies comparing outcome following LE and RS post-CRT were included. A pooled analysis was carried out using the Mantel-Haenszel statistical (random effects) model to identify differences in LR, OS and DFS between CRT + LE and CRT + RS.
Eight studies were suitable for pooled analyses of LR whereas five and four studies were analysed for OS and DFS, respectively. When RS was used as the reference group, LR rate was higher in the LE group. However, this was non-significant (odds ratio (OR) 1.29, confidence interval (CI) 0.72-2.31, p = 0.40). Similarly, no difference was observed in 10-year OS (OR 0.96, CI 0.38-2.43, p = 0.93) or 5-year DFS (OR 1.04, CI 0.61-1.76, p = 0.89). There was evidence of publication bias in studies used for DFS. Subgroup analysis of above outcomes in T3/any N stage cancers showed no difference in LE versus RS.
In the current evidence synthesis, there was no statistical difference in the LR, OS and DFS rates observed between patients treated with LE and RS for rectal cancer post-CRT. LE post-CRT may represent a viable alternative to RS for some patients wishing to avoid RS. However, further randomised studies are required to confirm these results.
低位直肠癌传统上采用新辅助放化疗(CRT),随后进行根治性手术(RS)。对于拒绝造口或不适合进行根治性手术的患者,另一种方法可能是在肿瘤有反应的情况下采用术前CRT和局部切除(LE)。本系统评价的目的是确定接受CRT+LE和CRT+RS治疗的患者在局部复发(LR)、总生存期(OS)和无病生存期(DFS)方面是否存在差异。
使用MEDLINE/PubMed/Ovid数据库和谷歌学术在1946年至2013年间进行文献检索。纳入比较CRT后LE和RS结局的研究。使用Mantel-Haenszel统计(随机效应)模型进行汇总分析,以确定CRT+LE和CRT+RS之间在LR、OS和DFS方面的差异。
八项研究适合进行LR的汇总分析,而分别有五项和四项研究进行了OS和DFS分析。当以RS作为参照组时,LE组的LR率更高。然而,这并不显著(优势比(OR)为1.29,置信区间(CI)为0.72-2.31,p=0.40)。同样,在10年总生存期(OR为0.96,CI为0.38-2.43,p=0.93)或5年无病生存期(OR为1.04,CI为0.61-1.76,p=0.89)方面未观察到差异。在用于DFS的研究中有发表偏倚的证据。T3/任何N期癌症上述结局的亚组分析显示LE与RS之间无差异。
在当前的证据综合分析中,接受CRT后LE和RS治疗的直肠癌患者在LR、OS和DFS率方面无统计学差异。CRT后的LE可能是一些希望避免RS的患者可行的替代方案。然而,需要进一步的随机研究来证实这些结果。